TCGA-62-A46O-01A-11R-A24H-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.430
- PROTEIN_SECRETION+0.400
- G2M_CHECKPOINT+0.370
- SPERMATOGENESIS+0.310
- MYC_TARGETS_V1+0.300
- ANDROGEN_RESPONSE+0.150
- UNFOLDED_PROTEIN_RESPONSE+0.150
- MITOTIC_SPINDLE+0.120
- MTORC1_SIGNALING+0.070
- PANCREAS_BETA_CELLS+0.050
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.520
- HEDGEHOG_SIGNALING-0.500
- IL6_JAK_STAT3_SIGNALING-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- INFLAMMATORY_RESPONSE-0.420
- ANGIOGENESIS-0.410
- TNFA_SIGNALING_VIA_NFKB-0.400
- KRAS_SIGNALING_UP-0.390
- APICAL_JUNCTION-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R6 | — | — | 0.895 |
| 2 | SRR35579806 | — | B | 0.884 |
| 3 | 20040104.LumB | — | B | 0.883 |
| 4 | BS_9NJHQE9F | medulloblastoma | — | 0.882 |
| 5 | SRR1797277 | — | cohortSC | 0.876 |
| 6 | R320 | — | — | 0.875 |
| 7 | R288 | — | — | 0.872 |
| 8 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.870 |
| 9 | SRR4195684 | — | — | 0.868 |
| 10 | 5af838ac-ab79-41c0-81fb-168cf9b1cf50 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |